Relapse of B-ALL following anti-CD19 CAR T-cell therapy can be globally divided into two groups using the flow cytometry evaluation of the expression of CD19: CD19-positive (70–80% of patients) and CD19-negative relapses (20–30% of patients) [22]. Here, CD19 is linked to acute lymphoblastic leukemia.